hotspot -WSS

hotspot

author：entertainment 2025-09-28 00:53:01 - browse：5686

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Vertex cell therapy lets patients with type 1 diabetes stop insulin

hotspot

focus

WSS

STAT wants to know your pick for a great summer read or listen

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Readout LOUD: Venture capital, Gilead, and more M&A

Why Novartis is going to walk from its acquisition of MorphoSys

A letter from the executive editor: The 2023 STATUS List

AstraZeneca lung cancer study comes in below expectations

focus

hotspot

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

AstraZeneca stays mum on Medicare drug pricing negotiations

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medicare Advantage plans can’t deny care with AI, CMS warns

Cancer drug shortages should be causing more outrage

'Screen and refer' systems are hurting patients

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Anesthesiologist group: stop taking Ozempic before surgery

Why Novartis is going to walk from its acquisition of MorphoSys

Wikipedia

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Drug cartel violence flares in western Mexico after vigilante leader's killing

Top private equity targets in 2023: cardiology, clinical trials, lasers

Why Novartis is going to walk from its acquisition of MorphoSys

Bernie brings in new pharma CEOs to talk drug prices

Canadians with cystic fibrosis outlive Americans by a decade

hotspot

hotspot

focus

knowledge